DexCom (NASDAQ:DXCM) Price Target Raised to $82.00 at JPMorgan Chase & Co.

DexCom (NASDAQ:DXCM) had its price target upped by JPMorgan Chase & Co. from $65.00 to $82.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical device company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential downside of 1.53% from the stock’s previous close.

A number of other research analysts also recently commented on DXCM. Wells Fargo & Company increased their price objective on DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Friday. BTIG Research reaffirmed a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of DexCom in a report on Friday. Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft initiated coverage on shares of DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price objective for the company. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $94.00 target price on shares of DexCom in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, DexCom has an average rating of “Moderate Buy” and a consensus target price of $87.54.

DexCom Stock Up 11.7%

Shares of DXCM stock traded up $8.73 on Friday, reaching $83.27. 6,585,737 shares of the stock were exchanged, compared to its average volume of 5,227,617. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The business’s 50 day moving average price is $72.91 and its 200 day moving average price is $69.10. The company has a market capitalization of $32.13 billion, a price-to-earnings ratio of 35.48, a PEG ratio of 1.24 and a beta of 1.45. DexCom has a twelve month low of $54.11 and a twelve month high of $87.00.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.DexCom’s quarterly revenue was up 13.1% on a year-over-year basis. During the same period last year, the firm earned $0.48 earnings per share. As a group, sell-side analysts expect that DexCom will post 2.57 earnings per share for the current fiscal year.

Insider Activity

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of DexCom stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the transaction, the director owned 52,852 shares of the company’s stock, valued at $3,917,918.76. The trade was a 7.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the completion of the sale, the director owned 25,007 shares of the company’s stock, valued at approximately $1,500,670.07. This represents a 3.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,506 shares of company stock worth $7,205,258 over the last ninety days. 0.28% of the stock is owned by corporate insiders.

Institutional Trading of DexCom

A number of large investors have recently bought and sold shares of DXCM. Reflection Asset Management purchased a new stake in shares of DexCom in the fourth quarter valued at about $25,000. Ascentis Independent Advisors acquired a new position in DexCom in the 1st quarter valued at about $25,000. MCF Advisors LLC purchased a new stake in DexCom during the 4th quarter valued at approximately $32,000. Wellington Grp LLC raised its stake in DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 475 shares during the last quarter. Finally, DV Equities LLC acquired a new stake in DexCom during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations. DexCom reported adjusted earnings of $0.70 per share, versus the $0.61 analyst consensus, while revenue rose 13.1% year over year to $1.31 billion, ahead of the $1.29 billion estimate. DexCom Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, citing strong demand for glucose monitors. The company is targeting nearly 50% U.S. conversion to its G7 15 Day system by year-end. Dexcom raises annual revenue forecast
• Positive Sentiment: Growth remained broad-based. U.S. revenue increased 11% to $933 million, while international revenue growth was stronger, supporting the bullish view of DexCom’s expanding CGM platform and newer products such as G7 15 Day and Stelo. DexCom Q2 2026 earnings call highlights
• Positive Sentiment: Analyst sentiment improved after the report. Wells Fargo raised its price target to $90 from $85 and maintained an overweight rating, while Benchmark lifted its target to $82 from $77 and assigned a buy rating. UBS also reaffirmed its buy rating with a $96 target.
• Neutral Sentiment: Institutional positioning was mixed. Several major investors, including Wellington Management, AllianceBernstein and UBS, added shares, while Jennison Associates and Nuveen reduced their holdings.
• Negative Sentiment: Insider trading remains a risk signal. Company insiders reported 14 open-market sales and no purchases during the past six months, including sales by Executive Chair Kevin Sayer and other executives.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.